Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics has opened an investigational new drug application (IND) with the FDA for nomacopan, targeting moderate to severe bullous pemphigoid (BP). Clinical recruitment is set to commence by mid-2021, pending COVID-19 restrictions. Nomacopan has received orphan drug designation from both the FDA and EMA. The Phase III trial aims to validate nomacopan’s unique therapeutic advantages, based on successful Phase II studies, with a focus on patient remission.
Akari Therapeutics announces a cooperative research and development agreement with the U.S. Army Institute of Surgical Research (USAISR) to study nomacopan for trauma treatment. This investigational drug targets inflammation in trauma cases, showing promise in conditions like traumatic brain injury and myocardial infarction. The study aims to evaluate nomacopan's efficacy in preclinical trauma models. With trauma being a leading cause of death under 45 years, Akari aims to address the lack of approved therapies, potentially benefiting both military and civilian patients.
Akari Therapeutics (Nasdaq: AKTX) announced new findings published in CELLS revealing the role of LTB4 in promoting VEGF-related retinal inflammation, contributing to wet AMD. In preclinical models, PAS-nomacopan, a long-acting version of their drug, significantly reduced neo-vascularization equivalent to the FDA-approved Eyelea®. The study demonstrated over 50% reduction in VEGF levels in uveitis models, highlighting PAS-nomacopan's dual mechanism of action that inhibits both LTB4 and complement C5, potentially offering new treatment avenues for eye diseases.
Akari Therapeutics (Nasdaq: AKTX) is advancing its therapeutic candidate, votucalis, which inhibits histamine and targets chronic neuropathic pain and dermatological conditions. New pre-clinical data demonstrate votucalis's effectiveness in blocking neuropathic pain symptoms and treating atopic dermatitis. Unlike conventional opioids, votucalis acts peripherally, minimizing CNS-related side effects. Local administration showed superior results compared to systemic treatment. Akari aims to initiate Phase II trials in 2022, positioning votucalis as a potential innovative solution in pain management and inflammatory diseases.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced CEO Clive Richardson will participate in two upcoming virtual investor conferences. The H.C. Wainwright BioConnect Conference will feature an on-demand presentation starting January 11, 2021. The ICR Conference 2021 is scheduled for January 14, 2021, at 10:00 a.m. ET. Investors can arrange virtual meetings during the ICR Conference. Akari develops therapies targeting orphan autoimmune and inflammatory diseases, with its lead drug candidate, nomacopan, inhibiting complement C5 and leukotriene B4 systems.
Akari Therapeutics, Plc (AKTX) announced progress in its clinical programs, including a pivotal Phase III trial for bullous pemphigoid (BP) expected to start in H1 2021, and enrollment for pediatric HSCT-TMA beginning in Europe. The company reported third-quarter financial results showing a net income of $1.4 million, reversing a loss from the previous year, largely due to increased other income and R&D tax credits. However, ongoing COVID-19 challenges may delay clinical trials and operations, impacting timelines. Cash as of September 30, 2020, stood at approximately $12.3 million.
Akari Therapeutics announced promising results from a long-term study of nomacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH). New data from 19 patients indicates that nomacopan is well-tolerated and has achieved a 79% transfusion independence rate among formerly transfusion-dependent patients treated for at least six months. The study demonstrated a significant reduction in monthly blood transfusions, with a 77% decline in unit requirements. These findings support nomacopan's potential for treating other complement dysregulation disorders, as noted by the company’s CEO.
Akari Therapeutics (Nasdaq: AKTX) announced findings from a two-year research collaboration with University College of London, highlighting the potential role of leukotriene B4 (LTB4) in retinal inflammation and degeneration. The study showed that the therapeutic administration of nomacopan effectively reduced retinal damage and inflammation in autoimmune uveitis models, rivaling the efficacy of standard steroid treatment, dexamethasone. Key findings reveal the decrease in Th17 cell and macrophage activity, indicating nomacopan's promise as a safer alternative to corticosteroids, which have significant side effects.
Akari Therapeutics has announced positive Phase II trial results for nomacopan, an experimental treatment for bullous pemphigoid (BP), a severe autoimmune disease. The FDA and EMA have approved progression to a Phase III randomized placebo-controlled study, which is set to begin in H1 2021. Nomacopan has received orphan drug designation in the U.S. and Europe. The upcoming poster presentation at the EADV Congress on October 29, 2020, will detail the safety and efficacy data. BP affects over 100,000 patients in the U.S. and Europe, with current treatments often resulting in severe side effects.
Akari Therapeutics (Nasdaq: AKTX) has received FDA clearance to proceed with a multi-center, double-blind randomized clinical study of its drug nomacopan for treating COVID-19 pneumonia in the U.S. and Brazil. This follows positive results from initial studies indicating effective use without up-dosing. The new study aims to evaluate the time to oxygen normalization and hospital discharge among over 120 patients, with treatment lasting up to 14 days. Nomacopan may address severe lung inflammation, a significant issue in COVID-19 pneumonia, by targeting multiple inflammatory pathways.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
